COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics

COMPASS Pathways PLC ADR (CMPS): $10.38

-0.20 (-1.89%)

POWR Rating

Component Grades













CMPS Stock Price Chart Interactive Chart >

Price chart for CMPS

CMPS Price/Volume Stats

Current price $10.38 52-week high $21.50
Prev. close $10.58 52-week low $6.54
Day low $10.28 Volume 190,200
Day high $10.53 Avg. volume 267,408
50-day MA $9.35 Dividend yield N/A
200-day MA $11.37 Market Cap 442.52M

COMPASS Pathways PLC ADR (CMPS) Company Bio

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.

CMPS Latest News Stream

Event/Time News Detail
Loading, please wait...

CMPS Latest Social Stream

Loading social stream, please wait...

View Full CMPS Social Stream

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS PATHWAYS PLC that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

10 Best Psychedelic Stocks to Buy According to Hedge Funds

In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research predicts that the psychedelic drugs market will expand at a compound annual growth rate […]

Yahoo | March 12, 2023

2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market

Enterprising investors who pay attention to this can set themselves up for future success by buying into great growth stocks while in the hard landing phase of the volatility. Two biopharma stocks are particularly appealing right now as buy candidates before the next bull market has a chance to buoy their shares once again. It develops liquid biopsies for cancer screening, treatment selection, treatment efficacy evaluation, and recurrence detection, which means that patients don't need to experience the invasiveness of a traditional biopsy to get the health information their doctors need to determine a course of treatment.

Yahoo | March 6, 2023

2 Growth Stocks With Incredible Potential in the Next 5 Years

Specifically, there are no guarantees that positive early results will lead to positive later-stage clinical trials results, despite yearslong efforts put in to develop these drugs and therapies. More often than not, pharma and biotech investors can only gauge the chances of a company's success by weighing the results of its clinical trials against its available cash runway.

Yahoo | March 6, 2023

COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows: Cowen 43rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetingsOppenheimer 33rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and hos

Yahoo | March 2, 2023

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call Transcript

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today’s conference, […]

Yahoo | March 2, 2023

Read More 'CMPS' Stories Here

CMPS Price Returns

1-mo 27.68%
3-mo 29.27%
6-mo -3.26%
1-year -19.47%
3-year N/A
5-year N/A
YTD 29.27%
2022 -63.67%
2021 -53.61%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8061 seconds.